These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39167784)

  • 21. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
    He H; Wen X; Zheng H
    Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.
    Yin Z; Yao Z; Chen D; Zhang Y; Weng G; Du X; Lin D; Xiao J; Sun Z; Zhang H; Liang X; Guo Z; Zhao W; Xuan L; Jiang X; Shi P; Liu Q; Ping B; Yu G
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):336. PubMed ID: 38969948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
    Liu Y; Li Y; Zhang R; Yu Z; Jing Y
    Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and Safety of Venetoclax-Based Induction Therapy in Acute Myeloid Leukemia].
    Feng J; Yuan RF; Tang HL; Bai QX; Yang L; Dong HJ; Liang R; Zhang T; Gu HT; Gao GX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):960-966. PubMed ID: 37551462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
    Jain AG; Volpe VO; Wang C; Ball S; Tobon K; Chan O; Padron E; Kuykendall A; Lancet JE; Komrokji R; Sallman DA; Sweet KL
    Ann Hematol; 2024 Sep; ():. PubMed ID: 39243312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
    Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
    Front Oncol; 2022; 12():858202. PubMed ID: 35433414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.
    Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
    Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
    Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia].
    Wang Y; Huang SL; Zhang XX; Bian MR; Lin GQ; Si YJ; Zhang B; Wan Y; Wang L; Zhang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):327-332. PubMed ID: 37096501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients.
    Yu H; Wang C; Lei Y; Li L; Wang H; Wang G; Xing L; Guan J; Song J; Wu Y; Liu H; Qu W; Wang X; Shao Z; Fu R
    Int Immunopharmacol; 2024 Jan; 127():111232. PubMed ID: 38091830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine.
    Zhang A; Johnson T; Abbott D; Phupitakphol T; Gutman JA; Pollyea DA; Koullias Y
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac486. PubMed ID: 36225746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
    Cui J; Chen X; Li C; Yan Q; Yuan G
    Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
    Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
    J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
    Pelland AA; Deschênes-Simard X; Savard X; Giguère P; Spillane D; Barabé F; Laroche V; Munger M; Gallagher G; Marcoux N; Cantin G; Chénard-Poirier M; Delage R; Lalancette M; Veilleux O; Assouline SE; Lemieux C
    Leuk Lymphoma; 2024 Dec; 65(13):1974-1982. PubMed ID: 39129334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
    Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
    Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
    Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
    Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
    Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
    Biochem Pharmacol; 2024 Oct; 228():116065. PubMed ID: 38373594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
    Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
    Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.